The vector of anti-CD20 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD20. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD20 antibody linked to FcεRIγ signaling domains. And the vector product was designed for the treatment of CD20+ malignancies , B-cell lymphoma, mantle cell lymphoma, CD20+ diffuse large cell lymphoma (DLCL), leukemias.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|CAR-NK-1-M327-G||Anti-CD20 scFv h(FcεRIγ) CARNK, pCDCAR1|
|CAR-T-2-M302-4Z||Anti-CD20 scFv h(CD4-CD3ζ) CART, pCDCAR1|
|CAR-NK-1-M327-2||Anti-CD20 scFv h(CD28) CARNK, pCDCAR1|
|VP-CAR-LC352||Lenti-CD20 CAR (scFv-CD28-OX40-CD3ζ, 1F5) Viral Particle|
|VP-TCR-C312||Lenti-CD20 T cell receptor (A94) Viral Particle|
|CAR-T-3-M302-2BZ||Anti-CD20 scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1|
|CAR-MZ018||Anti-CD20 (Leu-16) h(CD28-4-1BB-CD3ζ) CAR, pCDCAR1|
|CAR-NK-2-M327-4Z||Anti-CD20 scFv h(CD4-CD3ζ) CARNK, pCDCAR1|
|CAR-MZ056||Anti-CD20 (Ofatumumab) h(CD3ζ) CAR, pCDCAR1|
|CAR-T-2-M302-8Z||Anti-CD20 scFv h(CD8-CD3ζ) CART, pCDCAR1|
Copyright © 2007 - 2018 Creative Biolabs. All Rights Reserved